Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 10, 2023

SELL
$57.89 - $64.73 $28,945 - $32,365
-500 Reduced 10.88%
4,097 $237,000
Q2 2023

Jul 21, 2023

SELL
$63.71 - $70.74 $11,149 - $12,379
-175 Reduced 3.67%
4,597 $293,000
Q1 2023

Apr 13, 2023

SELL
$65.71 - $74.53 $37,454 - $42,482
-570 Reduced 10.67%
4,772 $330,000
Q3 2022

Oct 17, 2022

SELL
$0.13 - $76.84 $9 - $5,378
-70 Reduced 1.29%
5,342 $380,000
Q1 2022

May 06, 2022

SELL
$61.48 - $73.72 $15,984 - $19,167
-260 Reduced 4.58%
5,412 $395,000
Q4 2021

Jan 28, 2022

SELL
$53.63 - $62.52 $34,269 - $39,950
-639 Reduced 10.13%
5,672 $354,000
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $4,209 - $4,584
-68 Reduced 1.07%
6,311 $422,000
Q4 2020

Feb 02, 2021

SELL
$57.74 - $65.43 $4,041 - $4,580
-70 Reduced 1.09%
6,379 $396,000
Q3 2020

Oct 30, 2020

SELL
$57.43 - $63.64 $1,722 - $1,909
-30 Reduced 0.46%
6,449 $389,000
Q2 2020

Jul 29, 2020

SELL
$54.82 - $64.09 $4,769 - $5,575
-87 Reduced 1.33%
6,479 $381,000
Q1 2020

May 01, 2020

BUY
$46.4 - $67.43 $6,960 - $10,114
150 Added 2.34%
6,566 $366,000
Q4 2019

Jan 23, 2020

BUY
$49.21 - $64.19 $315,731 - $411,843
6,416 New
6,416 $412,000
Q3 2019

Nov 07, 2019

SELL
$42.77 - $50.71 $192,935 - $228,752
-4,511 Closed
0 $0
Q2 2019

Jul 31, 2019

SELL
$44.62 - $49.34 $12,448 - $13,765
-279 Reduced 5.82%
4,511 $205,000
Q1 2019

May 01, 2019

BUY
$45.12 - $53.8 $3,338 - $3,981
74 Added 1.57%
4,790 $229,000
Q3 2018

Nov 08, 2018

SELL
$55.19 - $62.25 $2,207 - $2,490
-40 Reduced 0.84%
4,716 $293,000
Q1 2018

May 07, 2018

BUY
$59.92 - $68.98 $30,738 - $35,386
513 Added 12.09%
4,756 $301,000
Q4 2017

Jan 31, 2018

SELL
$59.94 - $65.35 $3,956 - $4,313
-66 Reduced 1.53%
4,243 $260,000
Q3 2017

Oct 20, 2017

BUY
$55.23 - $63.74 $237,986 - $274,655
4,309
4,309 $275,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Weatherly Asset Management L. P. Portfolio

Follow Weatherly Asset Management L. P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weatherly Asset Management L. P., based on Form 13F filings with the SEC.

News

Stay updated on Weatherly Asset Management L. P. with notifications on news.